New Zealand markets open in 7 hours 12 minutes

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
11.880+0.140 (+1.19%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 26.73B
Enterprise value 24.92B
Trailing P/E N/A
Forward P/E 588.24
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.45
Price/book (mrq)1.53
Enterprise value/revenue 13.93
Enterprise value/EBITDA -10.46

Trading information

Stock price history

Beta (5Y monthly) 0.33
52-week change 3-53.50%
S&P500 52-week change 323.76%
52-week high 325.800
52-week low 39.170
50-day moving average 311.457
200-day moving average 315.701

Share statistics

Avg vol (3-month) 31.24M
Avg vol (10-day) 31.07M
Shares outstanding 5219.3M
Implied shares outstanding 62.28B
Float 8566.42M
% held by insiders 122.43%
% held by institutions 122.66%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -124.25%
Operating margin (ttm)-84.41%

Management effectiveness

Return on assets (ttm)-11.32%
Return on equity (ttm)-26.95%

Income statement

Revenue (ttm)1.63B
Revenue per share (ttm)1.66
Quarterly revenue growth (yoy)49.20%
Gross profit (ttm)N/A
EBITDA -1.92B
Net income avi to common (ttm)-2.02B
Diluted EPS (ttm)-2.260
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.56B
Total cash per share (mrq)4.67
Total debt (mrq)3.03B
Total debt/equity (mrq)43.16%
Current ratio (mrq)2.09
Book value per share (mrq)7.03

Cash flow statement

Operating cash flow (ttm)-1.66B
Levered free cash flow (ttm)-1.9B